Search results for "Type I"

showing 10 items of 966 documents

Management of hepatitis C virus genotype 4: recommendations of an international expert panel.

2011

HCV has been classified into no fewer than six major genotypes and a series of subtypes. Each HCV genotype is unique with respect to its nucleotide sequence, geographic distribution, and response to therapy. Genotypes 1, 2, and 3 are common throughout North America and Europe. HCV genotype 4 (HCV-4) is common in the Middle East and in Africa, where it is responsible for more than 80% of HCV infections. It has recently spread to several European countries. HCV-4 is considered a major cause of chronic hepatitis, cirrhosis, hepatocellular carcinoma, and liver transplantation in these regions. Although HCV-4 is the cause of approximately 20% of the 170 million cases of chronic hepatitis C in th…

medicine.medical_specialtyCarcinoma HepatocellularGenotypeHepatitis C virusHepacivirusHepacivirusmedicine.disease_causeAntiviral AgentsPolymorphism Single NucleotideFlaviviridaeInternal medicineGenotypeEpidemiologyRibavirinmedicineHumansClinical Trials as TopicHepatologybiologybusiness.industryInterleukinsLiver Neoplasmsvirus diseasesHepatitis CHepatitis C Chronicbiology.organism_classificationmedicine.diseaseVirologydigestive system diseasesRecombinant ProteinsLiver TransplantationNatural historyHepatocellular carcinomaInterferon Type IPractice Guidelines as TopicHCVInterferonsbusiness
researchProduct

Dihydrocucurbitacin B, isolated from Cayaponia tayuya, reduces damage in adjuvant-induced arthritis

2005

23,24-Dihydrocucurbitacin B, from the anti-rheumatic plant Cayaponia tayuya, was tested on arthritis induced by adjuvant to corroborate the anti-inflammatory properties of this plant. Arthritis was induced in Lewis rats; the resulting arthritic rats were then treated with dihydrocucurbitacin B (1 mg/kg orally, daily, 1 week). The effect of dihydrocucurbitacin B on the synthesis, release, and activity of pro-inflammatory enzymes (elastase, cyclooxygenase-2, and nitric oxide synthase-2) as well as its effect on different mediators (tumor necrosis factor-alpha and interleukin-1beta) were determined. Dihydrocucurbitacin B modified the evolution of the clinical symptoms, reducing the swelling an…

medicine.medical_specialtyCell Survivalmedicine.medical_treatmentAnti-Inflammatory AgentsAdministration OralNitric Oxide Synthase Type IIPainArthritisPlant RootsDinoprostoneCell LineNitric oxidechemistry.chemical_compoundSuperoxidesInternal medicinemedicineAnimalsLymphocytesNitritesPharmacologyDose-Response Relationship DrugPancreatic ElastasebiologyPlant Extractsbusiness.industryMacrophagesElastasemedicine.diseasebiology.organism_classificationArthritis ExperimentalTriterpenesCayaponia tayuyaRatsEnzyme ActivationNitric oxide synthaseCucurbitaceaeEndocrinologyCytokinechemistryCyclooxygenase 2Rats Inbred LewAntirheumatic AgentsToxicitybiology.proteinCytokinesFemaleTumor necrosis factor alphabusinessPhytotherapyEuropean Journal of Pharmacology
researchProduct

Intermittent ethanol exposure induces inflammatory brain damage and causes long-term behavioural alterations in adolescent rats

2007

Adolescent brain development seems to be important for the maturation of brain structures and behaviour. Intermittent binge ethanol drinking is common among adolescents, and this type of drinking can induce brain damage. Because we have demonstrated that chronic ethanol treatment induces inflammatory processes in the brain, we investigate whether intermittent ethanol intoxication enhances cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) in adolescent rats, and whether these mediators induce brain damage and cause permanent cognitive dysfunctions. Adolescent rats were exposed to ethanol (3.0 g/kg) for two consecutive days at 48-h intervals over 14 days. Levels of COX-2, iN…

medicine.medical_specialtyCerebellumProgrammed cell deathIndomethacinHippocampusNitric Oxide Synthase Type IIInflammationBrain damageMotor ActivityNeuropsychological TestsDiscrimination Learningchemistry.chemical_compoundindomethacinInternal medicineintermittent ethanol intoxicationmedicineAnimalsDrug InteractionsRats WistarAnalysis of VarianceNeocortexEthanolbiologyBehavior AnimalCell DeathEthanolCaspase 3General NeuroscienceAnti-Inflammatory Agents Non-SteroidalBrainRecognition PsychologyRatsNitric oxide synthasemedicine.anatomical_structureEndocrinologychemistryAnimals NewbornneurobehaviourCyclooxygenase 2inflammationAnesthesiabiology.proteinEncephalitisadolescencemedicine.symptomPsychologyPsychomotor Performance
researchProduct

Expressional down-regulation of neuronal-type nitric oxide synthase I by glucocorticoids in N1E-115 neuroblastoma cells.

1998

Neuronal-type nitric oxide synthase (NOS I) is involved in ischemia-induced brain damage, and glucocorticoids have been reported to protect from brain damage. This prompted us to investigate if the activity or expression of NOS I was influenced by glucocorticoids. We used the murine neuroblastoma cell line N1E-115 as our experimental model. Short-term incubation (30 min) of the N1E-115 cells with dexamethasone (10 nM to 1 microM) or hydrocortisone (100 nM to 10 microM) did not change the enzymatic activity of NOS I. However, the glucocorticoids inhibited NOS I mRNA expression in a concentration-dependent fashion (down to 53.3 +/- 2. 5% of control). In time-course experiments with 100 nM dex…

medicine.medical_specialtyDown-RegulationNitric Oxide Synthase Type IBiologyNitric OxideDexamethasonechemistry.chemical_compoundMiceNeuroblastomaInternal medicinemedicineTumor Cells CulturedAnimalsRNA MessengerGlucocorticoidsDexamethasonePharmacologyNeuronsMessenger RNAAntiglucocorticoidMifepristoneNitric oxide synthaseBlotEndocrinologychemistryCell culturebiology.proteinMolecular MedicineNitric Oxide SynthaseGlucocorticoidmedicine.drugMolecular pharmacology
researchProduct

Similar efficacy of low and standard doses of transdermal estradiol in controlling bone turnover in postmenopausal women

2006

To investigate the effects of a low transdermal estradiol dose on bone metabolism and to compare it with both the standard dose and absence of treatment.In this study performed in a third-level academic center, 66 healthy postmenopausal women underwent hormone therapy (HT) with patches containing estradiol at standard (0.050 mg/day, HT50, 33 women) or low dosage (0.025 mg/day, HT25, 33 women) and 70 women were without treatment (NT). The values (mean of three samples) of several bone biochemical parameters were compared between groups after adjusting for confounding factors. Bone mineral density (BMD) was assessed (by dual-energy X-ray absorptiometry) in the spine and hip in all cases, and …

medicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisCollagen Type IBone remodelingEndocrinologyBone DensityInternal medicinemedicineHumansOsteoporosis PostmenopausalTransdermalBone mineralAnalysis of VarianceDose-Response Relationship DrugEstradiolbusiness.industryEstrogen Replacement TherapyObstetrics and GynecologyMiddle AgedAlkaline Phosphatasemedicine.diseasePostmenopauseMenopauseDose–response relationshipEndocrinologyFemaleHormone therapyPeptidesDensitometrybusinessBiomarkersGynecological Endocrinology
researchProduct

Endothelial nitric oxide synthase in vascular disease: from marvel to menace.

2006

Nitric oxide (NO·) is an important protective molecule in the vasculature, and endothelial NO· synthase (eNOS) is responsible for most of the vascular NO· produced. A functional eNOS oxidizes its substrate l -arginine to l -citrulline and NO·. This normal function of eNOS requires dimerization of the enzyme, the presence of the substrate l -arginine, and the essential cofactor (6 R )-5,6,7,8-tetrahydro- l -biopterin (BH 4 ), one of the most potent naturally occurring reducing agents. Cardiovascular risk factors such as hypertension, hypercholesterolemia, diabetes mellitus, or chronic smoking stimulate the production of reactive oxygen species in the vascular wall. Nicotinamide adenine dinu…

medicine.medical_specialtyEndotheliumNitric Oxide Synthase Type IIINitric OxideNitric oxidechemistry.chemical_compoundEnosPhysiology (medical)Internal medicinemedicineAnimalsHumansVascular Diseaseschemistry.chemical_classificationReactive oxygen speciesbiologySuperoxidebusiness.industrybiology.organism_classificationNitric oxide synthaseOxidative Stressmedicine.anatomical_structureEndocrinologychemistrybiology.proteinEndothelium VascularCardiology and Cardiovascular MedicinebusinessReactive Oxygen SpeciesNicotinamide adenine dinucleotide phosphatePeroxynitriteCirculation
researchProduct

Orofacial clinical features in Arnold Chiari type I malformation: A case series

2017

Background Arnold Chiari malformation (ACM) is characterized by an anatomical defect at the base of the skull where the cerebellum and the spinal cord herniate through the foramen magnum into the cervical spinal canal. Among the subtypes of the condition, ACM type I (ACM-I) is particularly outstanding because of the severity of symptoms. This study aimed to analyze the orofacial clinical manifestations of patients with ACM-I, and discuss their demographic distribution and clinical features in light of the literature. Material and methods A case series with patients with ACM-I treated between 2012 and 2015 was described. The sample consisted of patients who were referred by the Department of…

medicine.medical_specialtyForamen magnumOral Medicine and Pathologybusiness.industryResearchDentistry030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Spinal cordTemporomandibular jointMasticatory force03 medical and health sciencesSkull0302 clinical medicinemedicine.anatomical_structureUNESCO::CIENCIAS MÉDICASmedicineOral and maxillofacial surgeryNeurosurgeryArnold-Chiari type I malformationbusinessGeneral Dentistry030217 neurology & neurosurgeryJournal of Clinical and Experimental Dentistry
researchProduct

Developmental and tumoral vascularization is regulated by G protein-coupled receptor kinase 2

2012

Tumor vessel dysfunction is a pivotal event in cancer progression. Using an in vivo neovascularization model, we identified G protein–coupled receptor kinase 2 (GRK2) as a key angiogenesis regulator. An impaired angiogenic response involving immature vessels was observed in mice hemizygous for Grk2 or in animals with endothelium-specific Grk2 silencing. ECs isolated from these animals displayed intrinsic alterations in migration, TGF-β signaling, and formation of tubular networks. Remarkably, an altered pattern of vessel growth and maturation was detected in postnatal retinas from endothelium-specific Grk2 knockout animals. Mouse embryos with systemic or endothelium-selective Grk2 ablation …

medicine.medical_specialtyG-Protein-Coupled Receptor Kinase 2Angiogenic SwitchAngiogenesisMedicinaActivin Receptors Type IIMelanoma ExperimentalReceptor Transforming Growth Factor-beta Type INeovascularization PhysiologicProtein Serine-Threonine KinasesBiologyMural cellGrk2Transforming Growth Factor beta1NeovascularizationMiceDownregulation and upregulationCell MovementPregnancyInternal medicinemedicineAnimalsHumansCell ProliferationHemizygoteMice KnockoutG protein-coupled receptor kinaseTumorNeovascularization PathologicEndothelial CellsRetinal VesselsG proteinGeneral MedicineCell biologyEndocrinologymedicine.anatomical_structurecardiovascular systemFemalePericyteSignal transductionmedicine.symptomActivin Receptors Type IReceptors Transforming Growth Factor betaSignal TransductionResearch Article
researchProduct

How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks fo…

2020

Familial hypercholesterolemia (FH) is a common genetic disorder of lipid metabolism, still underdiagnosed and undertreated in the general population. Pathology registers could play a crucial role in the creation of a comprehensive and integrated global approach to cover all aspects of this disease. Systematic data collection of patients affected by FH has increased dramatically worldwide in the past few years. Moreover, results from registers already established for the longest time showed their potentialities in the implementation of the knowledge of FH, comparing country-specific approaches and providing real-world data about identification, management and treatment of FH individuals in t…

medicine.medical_specialtyGenotypeFamilial hypercholesterolemiaPopulationFamilial hypercholesterolemiaDisease030204 cardiovascular system & hematologyHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineGenetic dyslipidaemiasFamilial hypercholesterolemia; Genetic dyslipidaemias; Pathology registersInternal MedicineHumansMedicineGenetic Predisposition to DiseaseRegistries030212 general & internal medicineeducationIntensive care medicineHypolipidemic Agentseducation.field_of_studybusiness.industryGenetic disorderDiagnostic algorithmsGeneral MedicinePathology registersmedicine.diseaseClinical PracticePhenotypeItalyCardiovascular DiseasesHeart Disease Risk FactorsDisease riskIdentification (biology)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessAlgorithmsAtherosclerosis Supplements
researchProduct

Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis

2009

Efficacy of retreatment with pegylated interferon (PEG-IFN) plus ribavirin of non-responders to standard or pegylated IFN plus ribavirin has been assessed in various studies, but sustained virologic response (SVR) rates are variable and factors influencing efficacy and tolerability still remain incompletely defined. We aimed to focus on SVR rates and to identify factors influencing them in this meta-analysis.MEDLINE as well as a manual search were used. Studies were included if they were controlled or uncontrolled trials, if they had been published as full-length papers and if they included non-responders to standard or pegylated IFN and ribavirin therapy. Fourteen trials were included in t…

medicine.medical_specialtyGenotypeHepatitis C virusHepacivirusmedicine.disease_causeAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundPharmacotherapyPegylated interferonInternal medicineRibavirinmedicineHumansHepatologybusiness.industryRibavirinvirus diseasesHepatitis CHepatitis C Chronicmedicine.diseaseRecombinant Proteinsdigestive system diseasesConfidence intervalTolerabilitychemistryMeta-analysisInterferon Type IImmunologyDrug Therapy Combinationbusinessmedicine.drugJournal of Hepatology
researchProduct